NewsRoom Articles - Page 120 of 154 - PsychedelicNewsWire (PNW)

FridaySep 18, 2020 12:54 pm

Cybin Corp. New CEO Set to Pave Path to Profitability, Grow IP Portfolio Organically

Cybin announces appointment of established pharma industry figure as new CEO Drysdale leverages 30 years of leadership, entrepreneurial experience in life-science space Announcement comes as Cybin sets out on path to profitability Cybin Corp., an innovative life science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, has announced the appointment of Mr. Doug Drysdale as the company’s Chief Executive Officer. With more than three decades of experience, the new leader recognizes psychedelics as a major breakthrough in treating mental health conditions. Drysdale joins Cybin to pave the road for the company’s rapid growth, underpinned by the recent strong push…

ThursdaySep 17, 2020 3:45 pm

UC Berkeley Center for Psychedelics Research and Education to Launch Soon

The University of California, Berkeley announced yesterday their plans to launch a new center that will be dedicated to psychedelics research and education. According to a press release, researchers at the facility will use psychedelic substances to study cognition, emotion and perception and their biological behavior bases in the human brain. The new facility will also be putting resources into ensuring that the public is informed about this field of research that is rapidly advancing. The UC Berkeley Center for the Science of Psychedelics will begin its studies with psilocybin, which is a psychedelic compound that is found in magic…

WednesdaySep 16, 2020 3:30 pm

The History of Psychedelic Medicine

Psychedelic substances have been used by various indigenous communities for both therapeutic and community purposes for many centuries. They have been used in various communities in different ways such as in initiations, rites of passage or for other personal, social and healing works. As we all know, the European colonizers relied on tactics and strategies that were built on breaking and disrespecting beliefs of different peoples and massacring cultures as a whole, in an attempt to ‘civilize’ them. The arrival of colonizers in the South and North American continents began the demonization of psychedelic substances and as a whole, the…

WednesdaySep 16, 2020 3:03 pm

Cybin Corp. Leads Out in Growing Billion-Dollar Nutraceutical, Psychedelic Markets

Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces. In 2019, the global nutraceutical market was valued at $382.51 billion. The…

WednesdaySep 16, 2020 12:59 pm

Pure Extract Technologies Inc. Building Presence in Billion-Dollar Mushroom Space

“Mushrooms are having a moment,” reports “Forbes” article Sector projected to benefit from both users, investors Pure Extracts Technologies well positioned to partner with organizations eyeing development in both functional, psychedelic products In what “Forbes” magazine is calling a “moment,” mushrooms are seeing rising popularity as growing numbers of people are interested in using the fungi as well as investing in them. This is great news for companies such as Pure Extract Technologies (“Pure Extracts”), a Canadian plant-based extraction company entering the functional medicinal mushroom space and collaborating in the psychedelic space “Psychedelics have been a mainstay for a millennia…

TuesdaySep 15, 2020 3:37 pm

New Study to Assess Psychedelics as Treatment for PTSD in Veterans

Recently, NeuroPharm Inc., a developer for psychedelic-based treatments announced that they would be collaborating with the Netherlands Leiden University Medical Center, on clinical trials centered on the treatment of PTSD in veterans. Psilocybin will be the first compound that will be studied. For those who may not have heard of psilocybin, it is a psychedelic substance found in about 200 mushroom species. This trial will involve 3 doses administered over a 12-week period and is said to be the first of its kind. Dr. Rakesh Jetly, NeuroPharm’s scientific advisor, explained that the trial primarily focused on veterans as PTSD impacted…

MondaySep 14, 2020 2:30 pm

Study Reveals Significant Increase in Americans Using LSD

In the sixties, psychedelics were all the rage and this continued, up until the year 1995, when Jerry Garcia, a figure who was at the forefront of the U.S. psychedelic culture, died. The consumption of LSD, which is a psychedelic substance, decreased in the whole country. Today, drugs such as psilocybin (an active ingredient found in magic mushrooms) and LSD are now being studied for the potential benefits they might possess that could help mankind. They are also being used to help treat anxiety as well as depression. It has been reported that some individuals are using the drugs daily,…

FridaySep 11, 2020 3:30 pm

Trip, The Guidance App That Helps You Explore Your Subconscious

If you would like to indulge in psychedelics but aren’t big on meeting up with people, queue social distancing, then having an app that stands watch during your trip is the next best option. One such company that focuses on this, is Field Trip Health. It centers on psychedelic-assisted therapy and is about to launch their Trip app in the coming weeks. This company, like many others that are coming up, belongs to a growing group of for-profit firms that are using psychedelic drugs such as Ketamine, MDMA and psilocybin to help treat and manage anxiety, depression and other mental…

ThursdaySep 10, 2020 3:00 pm

Dissolvable Psilocybin Strips Might Be the Future of Psychedelic Drug Treatments

In 2019, the United States FDA identified psilocybin, which is a psychoactive element in psychedelic mushrooms, as a breakthrough therapy. This means that enough evidence has been provided that indicates that a new treatment may be far more effective than the current treatments available. It also means that clinical trials can now be advanced into the drug testing phase. Companies who have been researching psilocybin would do well to grab this opportunity. In this case, psilocybin-assisted therapy has been used as therapy for MDD, short for Major Depressive Disorder and shows promise, in comparison to results using antidepressants. While many…

WednesdaySep 09, 2020 3:35 pm

Researchers Find That Psychedelic Substance Effects Are Akin to Mystical Experiences

Researchers in Finland are looking into the relationship between mystical experiences and psychedelic substances. Their new research study shows that the use of the Finnish version of the MEQ30 assessment to capture the effects of psychedelic substances on different individuals records the personal experiences accurately. Study author and postdoctoral researcher at Tampere University, Samuli Kangaslampi, stated that studies with both healthy volunteers and clinical populations and also population-based research, show that some individuals may undergo positive changes in their relationships as well as their well-being after the use of various psychedelic substances. This is despite the lack of evidence to…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000